Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies.
Carolin SchwakeThivya PakeerathanIngo KleiterMarius RingelsteinOrhan AktasMirjam Korporal-KuhnkeBrigitte WildemannSven JariusAntonios BayasRefik PulUlas CeylanSimon FaissnerKerstin HellwigAna Beatriz Ayroza Galvao Ribeiro GomesPhilipp LippsAnne-Katrin PröbstelTania KümpfelEva OswaldFlorian Then BerghClemens GödelMartin W HümmertCorinna TrebstRalf GoldIlya AyzenbergPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
Despite being lower than in healthy controls, the humoral vaccine response during anti-IL-6 receptor therapy was evident in all patients and substantially stronger compared to anti-CD20 treatment. No relevant disease activity occurred after mRNA vaccination against SARS-CoV-2.
Keyphrases
- sars cov
- disease activity
- immune response
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- coronavirus disease
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- peritoneal dialysis
- respiratory syndrome coronavirus
- prognostic factors
- juvenile idiopathic arthritis
- binding protein
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- nk cells